leisure time -WSS

leisure time

author：fashion 2025-10-03 01:03:25 - browse：54641

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Risky weight loss products often used by teens globally, per study

WSS

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Caregivers of transplant patients call for more support, training

GSK to buy asthma

Lack of health data on LGBTQ+ people has serious consequences

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

JPM 2024: Nvidia claims we're in biological revolution. Are we?

focus

leisure time

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

Change Healthcare: What is it, why does its cyberattack matter?

ChatGPT in medicine: STAT answers readers' burning questions

Harvard's David Sinclair gets blowback over aging

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Families look for replacement for GSK asthma drug Flovent

Supreme Court strikes down use of affirmative action

Microsoft's Peter Lee: Generative AI could help doctors be more human

The high cost of giving birth even with insurance

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

entertainment

Ozempic has benefits for kidney disease as well as diabetes

DeSantis can now import cheaper drugs. But will Biden get credit?

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

The untold story of TV’s first prescription drug ad

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Longer MASH drug regimen improved liver, Akero study finds

Wikipedia

entertainment

entertainment

hotspot